The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease.
Subjects' improvement in disease symptoms and overall Quality of life will be assessed during the study following DBS and compared with baseline. Additionally, the utilization of Image Guided Programming (IGP) when used as a planning tool for programming of patients is also evaluated.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Meets criteria established in locally applicable Vercise System Direction for Use
At least 18 years old
You may not be if
Meets any contraindication in the Vercise System locally applicable Directions for Use
Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Clareo Health | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
